01 / PROFILE
Peptide Profiles
Each entry explains what the peptide is, why people search for it, the proposed mechanism, and where the evidence stops.
Hype, hope, or real? Side-by-side: what the internet is claiming, what the evidence backs up, and whether it’s worth your money.
Educational reference. Not medical advice.
Reality checks
USADA this fall classified the mitochondrial exercise-mimetic peptide as prohibited in sport — ahead of any completed randomized controlled trial.
Generic liraglutide landed in U.S. pharmacies in 2025 — and by September 2026, it costs $226 while semaglutide commands $1,300.
RFK Jr. championed ipamorelin on Joe Rogan in February 2026. His own FDA advisory panel had already voted against it in October 2024.
An FDA panel voted yes on BPC-157 this summer — tied to a gut indication, not the recovery claims driving 73,000 monthly searches.
The world's biggest diabetes conference opens Monday in Milan — and Novo Nordisk is presenting the first real-world data on whether patients who switched from injections to the oral Wegovy pill held their results.
The peptide behind TB-500's recovery marketing is in cardiac trials right now — and recovery is its least-studied application.
Search the index
How we cut through the noise
01 / PROFILE
Each entry explains what the peptide is, why people search for it, the proposed mechanism, and where the evidence stops.
02 / NEWS
Clickbait headlines with real receipts. Daily article on a trending peptide — what people are claiming, what the evidence actually shows, where the line is.
03 / SAFETY
Profiles include risks, unknowns, approval context, and clear boundaries around dosing, sourcing, and personal medical advice.
04 / CATEGORY
Compare fitness and recovery, GLP-1 and metabolic, longevity and skin, endogenous biology, and approved clinical peptides.
Should you take it?
PeptideFactCheck separates approved use, human signal, early research, preclinical biology, anecdotes, and unknowns so curiosity does not become fake certainty.
Why you can trust the verdicts
IUPHAR/BPS, PubChem, UniProt, RCSB PDB, PubMed, Europe PMC, and ClinicalTrials.gov are used for molecular and research context.
FDA Orange Book, DailyMed, openFDA, and FDA safety communications are used for U.S. regulatory and label context.
Vendor pages, forum posts, and clinic claims can explain public interest, but they are not treated as authoritative evidence.